Skip to main content
Log in

Pharmacotherapy

Xanthine oxidase inhibition for relief of angina pectoris

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

Current medical therapies for chronic stable angina pectoris do not always render patients free of symptoms and may not be well tolerated. Xanthine oxidase inhibition with drugs such as allopurinol might be a promising new approach to treat these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341–1381 (2006).

    Article  Google Scholar 

  2. Lloyd-Jones, D. et al. Executive summary: heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation 121, 948–954 (2010).

    Article  Google Scholar 

  3. Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161–2167 (2010).

    Article  CAS  Google Scholar 

  4. Gislason, G. H. et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27, 1153–1158 (2006).

    Article  CAS  Google Scholar 

  5. Tardif, J. C. et al. for the ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 30, 540–548 (2009).

    Article  CAS  Google Scholar 

  6. Weintraub, W. S. et al. for the COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med. 359, 677–687 (2008).

    Article  CAS  Google Scholar 

  7. Serruys, P. W. et al. for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. 344, 1117–1124 (2001).

    Article  CAS  Google Scholar 

  8. Ciapponi, A., Pizarro, R. & Harrison, J. Trimetazidine for stable angina. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003614. doi: 10.1002/14651858.CD003614.pub2 (2005).

  9. Chaitman, B. R. et al. for the CARISA Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309–316 (2004).

    Article  CAS  Google Scholar 

  10. Gavin, A. D. & Struthers, A. D. Allopurinol reduces B-type natriuretic peptide concentrations and hemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91, 749–753 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ranil de Silva.

Ethics declarations

Competing interests

K. M. Fox is a consultant for, is in the speaker's bureau of, and received research support from Servier Laboratories. R. de Silva declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Silva, R., Fox, K. Xanthine oxidase inhibition for relief of angina pectoris. Nat Rev Cardiol 7, 603–604 (2010). https://doi.org/10.1038/nrcardio.2010.143

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.143

  • Springer Nature Limited

This article is cited by

Navigation